Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
Accepting patients
CARTITUDE-10
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
- CAR T Cell
- BCMA
- Phase 2
Accepting patients
QUINTESSENTIAL-2
Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
Accepting patients
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Accepting patients
TRIlogy-3
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
- Trispecific Antibody
- GPRC5D
- BCMA
- Phase 2
Accepting patients
CaMMouflage
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
- CAR T Cell (Allogeneic)
- BCMA
- Phase 1
- Has results
Accepting patients
DoMMino-1
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- CBP (CREB-binding Protein) Inhibitor
- Bromodomain Inhibitor
- P300 Inhibitor
- Phase 2
Not yet accepting
AZD4045
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- CAR T Cell (Allogeneic)
- T Cell Engager (TCE)
- BCMA
- Phase 1/2
Not yet accepting
BAFF CAR-T Cells (LMY-922)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
- CAR T Cell (Allogeneic)
- T Cell Engager (TCE)
- CD4
- BCMA
- CD8
- TACI
- BAFF
- Phase 1
Accepting patients
CAMPERR
cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse
- Observational Trial
Accepting patients
CERVINO
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
2 hidden based on your filters.Show All